## Phylogeny  
Tyrosine-protein kinase JAK2 is one of four Janus kinases (JAK1, JAK2, JAK3, TYK2). Orthologues are found from early metazoans to mammals, and the typical JAK domain architecture—N-terminal FERM and SH2-like modules followed by a regulatory pseudokinase domain (JH2) and a C-terminal catalytic kinase domain (JH1)—is conserved across vertebrates (Babon et al., 2014; Karjalainen, 2016; Mingione et al., 2023). JAK2 transcripts are detected in most mammalian tissues, consistent with its broad role in cytokine signalling (Kwon, 2022).  

## Reaction Catalyzed  
ATP + [protein]-L-tyrosine → ADP + [protein]-L-tyrosine-phosphate + H⁺ (Matsuda et al., 2004).  

## Cofactor Requirements  
Catalysis requires a divalent metal ion, predominantly Mg²⁺; Mn²⁺ can substitute in vitro (Endicott et al., 2012; Matsuda et al., 2004).  

## Substrate Specificity  
JAK2 phosphorylates tyrosine residues in the cytoplasmic tails of type I/II cytokine receptors and on STAT transcription factors. Peptide-array studies indicate sequence context around the target Tyr influences efficiency, although no single consensus motif is universal (Sanz et al., 2011; Deng et al., 2014). Additional cellular substrates include CDKN1B, histone H3 (Tyr41), and ARHGEF1 (Hammarén et al., 2015; Deng et al., 2014).  

## Structure  
JAK2 is a multidomain protein:  
• FERM domain (membrane/receptor binding)  
• SH2-like domain (stabilises receptor interaction)  
• Pseudokinase domain JH2 (binds ATP weakly; autoinhibits JH1)  
• Catalytic kinase domain JH1 (bilobal fold with conserved VAIK Lys, C-helix, DFG motif and activation loop)  

Tight JH2–JH1 and SH2–JH2 linker interactions modulate ATP affinity and allosteric regulation (Hubbard, 2018; Mingione et al., 2023; Kwon, 2022).  

## Regulation  
1. Autophosphorylation of Tyr1007 in the JH1 activation loop relieves autoinhibition (Babon et al., 2014; Matsuda et al., 2004).  
2. Intramolecular repression: JH2 interacts with JH1 to maintain low basal activity; mutations such as V617F disrupt this clamp and produce constitutive signalling (Hubbard, 2018; Barua et al., 2009).  
3. Additional phosphorylation, ubiquitination and dephosphorylation events fine-tune activity and receptor association (Babon et al., 2014; Mingione et al., 2023).  

## Function  
Upon cytokine binding to receptors (e.g., EPOR, GHR, PRLR, LEPR, MPL), receptor-bound JAK2 molecules trans-activate, phosphorylate receptor tyrosines, recruit STATs, and drive STAT dimerisation and nuclear gene regulation controlling haematopoiesis, immunity, proliferation and survival (Babon et al., 2014; Matsuda et al., 2004). JAK2 also:  
• Links cytokine signals to cell-cycle control via CDKN1B phosphorylation (Deng et al., 2014).  
• Modifies chromatin by phosphorylating histone H3 Tyr41, blocking CBX5 binding (Hammarén et al., 2015).  
• Contributes to vascular stress responses through ARHGEF1 phosphorylation and modulates KCNA3 channel expression (Deng et al., 2014).  
Its ubiquitous expression underscores its central role in multiple signalling pathways (Kwon, 2022).  

## Inhibitors  
Clinically approved ATP-competitive inhibitors such as ruxolitinib target the JH1 ATP-binding site for treatment of myeloproliferative neoplasms. Second-generation compounds aimed at allosteric or interdomain sites (e.g., within JH2 or the SH2-JH2 linker) are under development to improve specificity and reduce adverse effects (Kwon, 2022; Mingione et al., 2023).  

## Other Comments  
The disease-linked V617F mutation in JH2 abolishes autoinhibition and is a molecular hallmark of polycythaemia vera, essential thrombocythaemia and primary myelofibrosis (Barua et al., 2009; Hubbard, 2018). Combination therapeutic strategies targeting multiple nodes in the JAK2 network are being explored (Mingione et al., 2023).  

## 9. References  
Babon, J. J., Lucet, I. S., Murphy, J. M., Nicola, N. A., & Varghese, L. N. (2014). The molecular regulation of Janus kinase (JAK) activation. Biochemical Journal, 462(1), 1–13. https://doi.org/10.1042/BJ20140712  

Barua, D., Faeder, J. R., & Haugh, J. M. (2009). A bipolar clamp mechanism for activation of JAK-family protein tyrosine kinases. PLoS Computational Biology, 5(4), e1000364. https://doi.org/10.1371/journal.pcbi.1000364  

Deng, Y., Alicea-Velázquez, N. L., Bannwarth, L., Lehtonen, S. I., Boggon, T. J., Cheng, H.-C., Hytönen, V. P., & Turk, B. E. (2014). Global analysis of human non-receptor tyrosine kinase specificity using high-density peptide microarrays. Journal of Proteome Research, 13(8), 4339–4346. https://doi.org/10.1021/pr500503q  

Endicott, J. A., Noble, M. E. M., & Johnson, L. N. (2012). The structural basis for control of eukaryotic protein kinases. Annual Review of Biochemistry, 81, 587–613. https://doi.org/10.1146/annurev-biochem-052410-090317  

Hammarén, H. M., Ungureanu, D., Grisouard, J., Skoda, R. C., Hubbard, S. R., & Silvennoinen, O. (2015). ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proceedings of the National Academy of Sciences, 112(15), 4642–4647. https://doi.org/10.1073/pnas.1423201112  

Hubbard, S. R. (2018). Mechanistic insights into regulation of JAK2 tyrosine kinase. Frontiers in Endocrinology, 8, 361. https://doi.org/10.3389/fendo.2017.00361  

Karjalainen, A. (2016). Interactions of JAK2 pseudokinase and kinase domains in health and disease. [Doctoral dissertation].  

Kwon, S. (2022). Molecular dissection of Janus kinases as drug targets for inflammatory diseases. Frontiers in Immunology, 13, 1075192. https://doi.org/10.3389/fimmu.2022.1075192  

Matsuda, T., Feng, J., Witthuhn, B. A., Sekine, Y., & Ihle, J. N. (2004). Determination of the trans-phosphorylation sites of JAK2 kinase. Biochemical and Biophysical Research Communications, 325(2), 586–594. https://doi.org/10.1016/j.bbrc.2004.10.071  

Min, X., Ungureanu, D., Maxwell, S., Hammarén, H., Thibault, S., Hillert, E.-K., Ayres, M., Greenfield, B., Eksterowicz, J., Gabel, C., Walker, N., Silvennoinen, O., & Wang, Z. (2015). Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2). Journal of Biological Chemistry, 290(45), 27261–27270. https://doi.org/10.1074/jbc.M115.672048  

Mingione, V. R., Paung, Y., Outhwaite, I. R., & Seeliger, M. A. (2023). Allosteric regulation and inhibition of protein kinases. Biochemical Society Transactions, 51(1), 373–385. https://doi.org/10.1042/BST20220940  

Sanz, A., Ungureanu, D., Silvennoinen, O., & Yadav, S. S. (2011). Analysis of JAK2 catalytic function by peptide microarrays: The role of the JH2 domain and V617F mutation. PLoS ONE, 6(4), e18522. https://doi.org/10.1371/journal.pone.0018522